Stabilitech logo — Advancing vaccine and biopharmaceutical stability with pione...

Stabilitech

Advancing vaccine and biopharmaceutical stability with pioneering formulations.

Founded 2002 Series C Total: $9.00M Biotechnology, Pharmaceutical

General Information

Company Name Stabilitech
Founded Year 2002
Industries Biotechnology, Pharmaceutical
Funding Stage Series C
Social

Get notified when Stabilitech moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Stabilitech

Stabilitech, founded in 2002 by Dr. Jeff Drew, is a privately-owned enterprise based in the London Bioscience Innovation Centre, dedicated to stabilizing sensitive biological molecules, including vaccines and biopharmaceuticals. The company's mission revolves around enhancing the stability of these critical components through proprietary formulation technology. This innovative approach ensures the long-term stability of various thermally sensitive viruses, vaccines, and biopharmaceuticals. Notably, the compositions consist of chemical ingredients already approved for clinical use, either as injectables or listed as Generally Regarded As Safe (GRAS). Stabilitech's strategic focus is on commercializing its technology through partnerships with major pharmaceutical and biotechnology firms, as well as global health organizations. In August 2011, the company secured a significant $3.50M Series C investment.

Stabilitech, founded in 2002 by Dr. Jeff Drew, is a privately-owned enterprise based in the London Bioscience Innovation Centre, dedicated to stabilizing sensitive biological molecules, including vaccines and biopharmaceuticals. The company's mission revolves around enhancing the stability of these critical components through proprietary formulation technology. This innovative approach ensures the long-term stability of various thermally sensitive viruses, vaccines, and biopharmaceuticals. Notably, the compositions consist of chemical ingredients already approved for clinical use, either as injectables or listed as Generally Regarded As Safe (GRAS). Stabilitech's strategic focus is on commercializing its technology through partnerships with major pharmaceutical and biotechnology firms, as well as global health organizations. In August 2011, the company secured a significant $3.50M Series C investment.

Taxonomy: biopharmaceuticals, vaccines, stabilization technology, thermally sensitive viruses, formulation technology, biological molecules, drug stability, pharmaceutical partnerships, global health organizations

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• - 06 Aug 2011
Debt Financing •••••• - 13 May 2011
Venture Round •••••• - 12 Mar 2009

Stabilitech Alternatives & Competitors

Stabilitech vs

Enhance protein-based drug discovery with rapid optimization of solubility and stability using our h...

Biotechnology, Health Care
Stabilitech vs

Delivering next-generation nanovaccines and biopharmaceuticals faster for global health protection.

Series Unknown
Biopharma, Biotechnology
Stabilitech vs

Discover the Power of Insulation

Seed
16 employees
Biopharma, Biotechnology

FAQ About Stabilitech

Advancing vaccine and biopharmaceutical stability with pioneering formulations.
Stabilitech was founded in 2002.
Stabilitech operates in the following industries: Biotechnology, Pharmaceutical.
Stabilitech has completed 3 funding rounds, raising a total of $9.00M. The latest funding stage is Series C.
Top alternatives and competitors to Stabilitech include Soluble Therapeutics, NTpharma, KROSSLINKER Aerogel Solutions, Vaxxas, AeroSafe Global. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stabilitech and Soluble Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Stabilitech and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy